Medication info
Lova Tablet 20 Milligrams (Rosuvastatin Calcium)

Lova Tablet 20 Milligrams (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Wonkwang Pharmaceutical Co., Ltd.
Appearance
Pink, round, film-coated tablets
Packaging
PTP packaging - 30 tablets/PTP [30 tablets (15 tablets/PTP × 2)]
Approval status
Active

MFDS item code 202001508 · Approved 2020.03.03 · Insurance code 662600960

Summary

Main use
Improvement of dyslipidemia; reduction of cardiovascular disease risk; inhibition of atherosclerosis progression
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. The dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which is sufficient to achieve control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses above 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Wonkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; reduction of cardiovascular disease risk; inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct in patients with hypercholesterolemia and mixed dyslipidemia when diet and exercise alone are insufficient. It particularly helps lower total cholesterol and LDL cholesterol in patients with homozygous familial hypercholesterolemia or hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is also used as an adjunct for dietary therapy in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, effectively reducing cholesterol levels. Furthermore, it can be used as an adjunct in the treatment of primary dysbetalipoproteinemia. For middle-aged and older patients at high risk of cardiovascular disease, it helps reduce the risks of stroke, myocardial infarction, and arterial revascularization. Thus, this medication is effectively used for various dyslipidemias and the reduction of cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. The dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which is sufficient to achieve control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses above 20 milligrams in pediatric patients.) Adjust the dose individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For instance, it should not be given to patients who are allergic to this medication, have severely impaired liver function, have muscular diseases, have significantly reduced kidney function, or are pregnant or breastfeeding women. Additionally, high doses of this medication are contraindicated in patients at high risk for muscle damage, and in such cases, the dosage should be adjusted or avoided. This medication contains lactose and should not be taken by patients with lactose intolerance. Regular liver function tests are important before starting and during treatment with this medication. Patients with a history of liver disease or excessive alcohol consumption should be particularly cautious. If symptoms such as myalgia, muscle weakness, fatigue, and fever occur, they should immediately inform their doctor, and muscle enzyme tests should be performed if necessary to check for muscle damage. This medication can rarely cause serious skin reactions or liver damage, so if a rash, jaundice, or severe itching occurs, it must be discontinued immediately, and a healthcare provider should be consulted. Drug interactions may occur when taken with other medications, so any current medications should be disclosed to healthcare providers. Caution is advised when taken with specific antiviral drugs, immunosuppressants, antifungals, antibiotics, and fibrate medications. Women of childbearing potential should use appropriate contraception while taking this medication, and should discontinue it immediately if pregnancy is confirmed. In case of overdose, there is no specific antidote, so appropriate treatment and monitoring of liver function and muscle enzymes according to symptoms is necessary. This medication does not appear to have a significant impact on the ability to drive or operate machinery; however, caution is advised as dizziness may occur. This medication may show higher systemic exposure in Asian patients, so dose adjustment may be necessary.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia accompanied by systemic symptoms drug reaction syndrome, drug eruption resembling lichen planus, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, dysesthesia, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to store it at room temperature between 1 and 30 degrees Celsius, away from extreme heat or cold.

Appearance and packaging

Appearance

Pink, round, film-coated tablets

Package unit

PTP packaging - 30 tablets/PTP [30 tablets (15 tablets/PTP × 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.